Cargando…
Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial
BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is associated with reduced risk for major coronary events. Despite statin efficacy, a considerable proportion of statin-treated hypercholesterolemic patients fail to reach therapeutic LDL-C targets as defined by guidelines. This study...
Autores principales: | Yu, Chih-Chieh, Lai, Wen-Ter, Shih, Kuang-Chung, Lin, Tsung-Hsien, Lu, Chieh-Hua, Lai, Hung-Jen, Hanson, Mary E, Hwang, Juey-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403927/ https://www.ncbi.nlm.nih.gov/pubmed/22621316 http://dx.doi.org/10.1186/1756-0500-5-251 |
Ejemplares similares
-
Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients
por: Oh, Min Seok, et al.
Publicado: (2011) -
Ongoing Clinical Trials of the Pleiotropic Effects of Statins
por: Davignon, Jean, et al.
Publicado: (2005) -
The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus
por: Sharifi, Faranak, et al.
Publicado: (2013) -
Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers
por: Wu, Na-Qiong, et al.
Publicado: (2018) -
Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
por: Abramson, Beth L, et al.
Publicado: (2011)